Abstract
Optimal therapy for uveitis is predicated on an understanding of the predominant pathophysiologic mechanism(s) responsible for the specific disorder. To that end, antiviral, antibacterial, antiprotozoal, and antihelminthic agents, as well as specific anti-inflammatory and immunosuppressive medications, can be delivered via topical, regional, and systemic routes in specific circumstances. Whatever the form of therapy, the general goals are similar: to improve comfort, to reduce the severity and frequency of the inflammation, to prevent complications of the uveitis, to avoid treatment complications and drug side effects, and ultimately to preserve sight.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aronson SB. Potential pathways for anti-inflammatory therapy. Trans Am Acad Ophthalmol Otolaryngol. 1975; 79: 62
Opremcak EM. Topical therapy for iritis. Focal Points. 1991; 9: 1.
Tsai I, Till GO, Marak GE Jr. Effects of mydriatic agents on neutrophil migration, Ophthalmic Res, in press.
Clamen HN. Anti-inflammatory effects of corticosteroids. Clin Immunol Allergy. 1984; 4: 317.
Leibowitz HM, Kupferman A. Bioavailability and therapeutic effectiveness of topically administered corticosteroids. Trans Am Acad Ophthalmol Otolaryngol. 1975; 79: 78.
Urban RC Jr, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol. 1986; 31: 102.
Black RL, Oglesby RB, von Sallmann L, et al. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA. 1960; 174: 166.
Hodapp EA, Kass MA. Corticosteroid- induced glaucoma. In: Ritch R, Shields MB, eds. The Secondary Glaucomas. St. Louis: CV Mosby; 1982.
Armaly MF. Statistical attributes of steroid hypertensive response in the clinically normal eye. Invest Ophthalmol. 1965; 4: 187.
Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol. 1965; 4: 198.
Mindel J, Goldberg J, Tavitian H. Similarity of the intraocular pressure response to different corticosteroid esters when compliance is controlled. Ophthalmology. 1979; 86: 98.
Cantrill HL, Palmberg PF, Zink HA, et al. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975; 79: 1012.
Opremcak EM. Nonsteroidal anti-inflammatory drugs. In: Haverner WH, ed. Havener’s Ocular Pharmacology. St. Louis: Mosby-Year Book; 1994.
Keates RH, McGowan KA. Clinical trial of flurbiprofen to maintain pupillary dilation during cataract surgery. Ann Ophthalmol. 1984; 16: 919.
Flurbiprofen—an ophthalmic NSAID. Med Lett Ther. 1987; 29: 58.
Araie M, Sawa M, Takase M. Topical flurbi-profen and diclofenac suppress blood-aqueous barrier breakdown in cataract surgery: a fluorometric study. Jpn J Ophthalmol. 1983; 27: 535.
Araie M, Sawa M, Takase M. Effect of topical indomethacin on the blood-aqueous barrier after intracapsular extraction of a senile cataract—a fluorophotometric study. Jpn J Ophthalmol. 1981; 25: 237.
Eguchi K, Ohara K, Tobari I, et al. Effects of topical indomethacin on suppression of in-flammation after ocular surgeries—double mask study of anti-inflammatory effects on the intracapsular lens extraction. Acta Soc Ophthalmol Jpn. 1982; 86: 2198.
Mochizuki M, Sawa M, Masuda K. Topical indomethacin in intracapsular extraction of a senile cataract. Jpn J Ophthalmol 1977; 21: 215.
Sanders DR, Kraff MC, Leiberman HL, et al. Breakdown and re-establishment of blood- aqueous barrier with implant surgery. Arch Ophthalmol 1982; 100: 588.
Flach AJ, Kraff MC, Sanders DR, Tanenbaum L. The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexametha- sone sodium phosphate solution on postsurgical blood-aqueous barrier. Arch Ophthalmol 1988; 106: 480.
Flach AJ, Jaffe NS, Akers WA. The effect of ketorolac tromethamine in reducing postoperative inflammation: double mask parallel comparison with dexamethasone. Ann Ophthalmol 1989; 21: 407.
Sabiiston D, Tessler H, Sumers K, et al. Reduction of inflammation following cataract surgery by the nonsteroidal anti-inflammatory drug flurbiprofen. Ophthalmic Surg. 1987; 18: 873.
Flach AJ, Lavelle CJ, Olander KW, et al. The effect of ketorolac tomethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation. Ophthalmology. 1988; 95: 1279.
Hurvitz LM, Spaeth GL, Zakhour I, et al. A comparison of the effect of flurbiprofen dexamethasone and placebo on cyclocryotherapy-induced inflammation. Ophthal Surg. 1984; 15: 394.
Stark WJ, Worthen DM, Halladay JT. The FDA report on intraocular lenses. Ophthalmology. 1983; 90: 311.
Irvine AR. Cystoid macular edema. Surv Ophthalmol 1976; 21: 1.
The Miami Study Group. Cystoid macular edema in aphakic and pseudophakic eyes. Am J Ophthalmol 1979; 88: 45.
Jampol LM. Pharmacologic therapy of aphakic and pseudophakic cystoid maculae edema. Ophthalmology. 1985; 92: 807.
Yannuzzi LA. A perspective on the treat-ment of aphakic cystoid macular edema. Surv Ophthalmol 1984; 28: 540.
Miyake K, Sakamura S, Miura H. Long-term follow-up study on prevention of aphakic cystoid macular edema by topical indomethacin. Br J Ophthalmol 1980; 64: 324.
Yannuzzi LA, Landau AN, Turtz Al. Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology. 1981; 88: 947.
Kraff MC, Sanders DR, Jampol LM, et al. Prophylaxis of psuedophakic cystoid macular edema with topical indomethacin. Ophthalmology. 1982; 89: 885.
Miyake K. Indomethacin in the treatment of postoperative cystoid macular edema. Surv Ophthalmol 1984; 28: 554.
Burnett J, Tessler H, Isenberg S, Tso MOM. Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macu-lar edema. Ophthal Surg. 1983; 14: 150.
Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and psuedophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991; 112: 514.
BenEzra D, Maftzir G, de Courten C, Timonen P. Ocular penetration of cyclosporin A. III. The human eye. Br J Ophthalmol 1990; 74: 350.
Schlaegel TF Jr. Essentials of Uveitis. Boston: Little Brown; 1969: 41.
Smith RE, Nozik RA. The nonspecific treatment of uveitis. In: Carol-lynn Brown, ed. Uveitis. A Clinical Approach to Diagnosis and Management. 2nd ed. Baltimore: Williams & Wilkins; 1989: 51.
Watson PG. The diagnosis and management of scleritis. Ophthalmology. 1980; 87: 716.
Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med. 1984; 310: 563.
Langman MJS. Ulcer complications and nonsteroidal anti-inflammatory drugs. Am J Med. 1988; 84 (suppl 2A): 15.
Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs—differences and sim-ilarities. N Engl J Med. 1991; 324: 1716.
Hamberg M, Svenson J, Samuelsson B. Thromboxanes: new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci 1975; 72: 2994.
Samuelsson B, Borgeat P, Hammarstrom S, et al. Leukotrienes: a new group of biologically active compounds. In: Samuelsson B, Ramwell PW, Paoletti R, eds. Leukotrienes and Other Lipoxygenase Products. New York: Raven Press; 1980: 1.
Kass MA, Holmberg NJ. Prostaglandin and thromboxane synthesis by microsomes of rabbit ocular tissues. Invest Ophthalmol Vis Sei. 1979; 18: 166.
Bhattacherjee P, Eakins KE. A comparison of the inhibitory activity of compounds on ocular prostaglandin biosynthesis. Invest Ophthalmol Vis Sei. 1974; 13: 967.
van Haeringen NJ, Oosterhuis JA, van Delft JL, et al. A comparison of the effects on nonsteroidal compounds on the disruption of the blood-aqueous barrier. Exp Eye Res. 1982; 35: 271.
Van den Ouweland FA, Gribnau FWJ, van Ginneken CAM, et al. Naproxen kinetics and disease activity in rheumatoid arthritis: a within patient study. Clin Pharmacol Ther. 1988; 43: 79.
Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum. 1982; 25: 1013.
Netter P, Lapicque F, Bannwarth B, et al. Diffusion of intramuscular ketoprofen into the cerebrospinal fluid. Eur J Clin Pharmacol. 1985; 29: 319.
Orme M, Baber N, Keenan J, et al. Pharmacokinetics and biochemical effects in responders and non-responders to nonsteroidal anti-inflammatory drugs. Scand J Rheum. 1981; 39 (suppl): 19.
Huskisson EC, Woolf DL, Balme HW, et al. Four new anti-inflammatory drugs: responses and variations. Br Med J. 1976; 1: 1048.
Gall EP, Caperton JF, McComb JE, et al. Clinical comparison of ibuprofen, fenoprofen calcium, naproxen, tolmectin sodium in rheumatoid arthritis. J Rheumatol. 1982; 9: 402.
Heller CA, Ingelfinger JA, Goldman P. Nonsteroidal anti-inflammatory drugs and aspirin—analyzing the scores. Pharmacotherapy. 1985; 5: 30.
Watson PG, Hayreh SS. Scleritis and epi-scleritis. Br J Ophthalmol. 1976; 60: 163.
Bjarnason I, Zanelli G, Prowse P, et al. Blood and protein loss via small intestinal inflammation induced by nonsteroidal anti-inflammatory drugs. Lancet. 1987; 2: 711.
Henry DA. Side effects of nonsteroidal antiinflammatory drugs. Baillieres Clin Rheumatol. 1988; 2: 425.
Beard K, Walker AM, Perera DR, Jick H. Nonsteroidal anti-inflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly. Arch Intern Med. 1987; 147: 1621.
Sommerville K, Faulkner G, Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet. 1986; 1: 462.
Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. Br Med J. 1990; 300: 278.
Soil AH. Pathogenesis of peptic ulcer and implication for therapy. N Engl J Med. 1990; 322: 909.
Garella S, Matarese RA. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine. 1984; 64: 165.
Lifschitz MD. Prostaglandins and renal blood flow: in vivo studies. Kidney Int. 1981; 19: 802.
Mondino BJ, Phinney RB. Treatment of scleritis with combined oral prednisone and indomethacin therapy. Am J Ophthalmol. 1988; 106: 473.
Foster CS. Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology. 1980; 87: 140.
Rao NA, Patchett R, Fernandez MA, et al. Treatment of experimental granulomatous uveitis by lipoxygenase and cyclo-oxygenase inhibitors. Arch Ophthalmol. 1987; 105: 413.
Howes EL, McKay DG. The effect of aspirin and indomethacin on the ocular response to circulating bacterial endotoxin in the rabbit. Invest Ophthalmol. 1976; 15: 648.
Olson NY, Lindsley CB, Godfrey WA. Nonsteroidal anti-inflammatory drug therapy in chronic childhood iridocyclitis. Am J Dis Child. 1988; 142: 1289.
Nussenblatt RB, Palestine AG. Philosophy, goals, and approaches to medical therapy. In: David K. Marshall, ed. Uveitis. Fundamentals and Clinical Practice. Chicago: Year Book Medical Publishers; 1989: 104.
Dinning WJ. Therapy—selected topics. In: Kraus-Mackiw E, O’Connor GR, eds. Uveitis. Pathology and Therapy. 2nd rev. ed. New York: Thieme Medical Publishers; 1986: 204.
Fauci AS. Clinical aspects of immunosuppression: use of cytotoxic agents and corticosteroids. In: Bellanti IA, ed. Immunology II. Philadelphia: WB Saunders; 1978.
Wong VG. Methotrexate treatment of uveal disease. Am J Med Sci. 1966; 251: 239.
Wong VG. Immunosuppressive therapy of ocular inflammatory diseases. Arch Ophthalmol. 1969; 81: 628.
Foster CS. Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology (Rochester). 1980; 87: 140.
Buckley CE III, Gills JP Jr. Cyclophos-phamide therapy of Behcet’s disease. J Allergy. 1969; 43: 273.
Buckley CE III, Gills JP Jr. Cyclophosphamide therapy of peripheral uveitis. Arch Intern Med. 1969; 124: 29.
Andrasch RH, Pirofsky B, Burns RP. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol. 1978; 96: 247.
Newell FW, Krill AE. Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc UK. 1967; 87: 499.
Palacios R, Moller G. Cyclosporin A blocks receptors for HLA-DR antigens on T cells. Nature. 1981; 290: 792.
Beveridge T. Pharmacokinetics and metabolism of cyclosporin A. In: White DJG, ed. Cyclosporin A. New York: Elsevier Biomedical Press; 1982: 35.
Nussenblatt RB, Palestine AG. Cyclosporine: immunology, pharmacology, and therapeutic uses. Surv Ophthalmol. 1986; 31: 159.
Bunjes D, Hardt C, Rollinghoff M, et al. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell respones by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol. 1981; 11: 657.
Kaufman Y, Chang AE, Robb RJ, et al. Mechanism of action of cyclosporin A: inhibition of lymphokine secretion studied with antigen-stimulated T-cell hybridomas. J Immunol. 1984; 133: 3107.
Bendtzen K, Dinarello CA. Mechanism of action of cyclosporine A. Scand J Immunol. 1984; 20: 43.
Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983; 96: 275.
Nussenblatt RB, Palestine AG, Rook AH, et al. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet. 1983; 2: 235.
Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine therapy for uveitis: long-term follow-up. J Ocular Pharmacol. 1985; 1: 369.
Feutren G, Mihaatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med. 1992; 326: 1654.
Austin HA III, Palestine AG, Sabnis SG, et al. Evolution of cyclosporin nephrotoxicity in patients treated for autoimmune uveitis. Am J Nephrol. 1989; 9: 392.
Mochizuki M, Ikeda E, Shirao M, et al. Pre-clinical and clinical study of FK506 in uveitis. Curr Eye Res. 1992;ll(suppl):87.
Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol. 1993; 115: 763.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag New York Inc.
About this chapter
Cite this chapter
Mitchel Opremcak, E. (1995). Medical Therapy for Uveitis. In: Uveitis. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-4174-4_5
Download citation
DOI: https://doi.org/10.1007/978-1-4612-4174-4_5
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-8685-1
Online ISBN: 978-1-4612-4174-4
eBook Packages: Springer Book Archive